{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T19:59:34Z","timestamp":1760731174279,"version":"3.37.3"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T00:00:00Z","timestamp":1554422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001026","name":"National Breast Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008018","name":"Victorian Cancer Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Loss-of-function variants in RAD51C are associated with familial ovarian cancer, but its role in hereditary breast cancer remains unclear. The aim of this study was to couple breast tumor sequencing with case-control data to clarify the contribution of RAD51C to hereditary breast cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>RAD51C was sequenced in 3080 breast cancer index cases that were negative in BRCA1\/2 clinical tests and 4840 population-matched cancer-free controls. Pedigree and pathology data were analyzed. Nine breast cancers and one ovarian cancer from RAD51C variant carriers were sequenced to identify biallelic inactivation of RAD51C, copy number variation, mutational signatures, and the spectrum of somatic mutations in breast cancer driver genes. The promoter of RAD51C was analyzed for DNA methylation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A statistically significant excess of loss-of-function variants was identified in 3080 cases (0.4%) compared with 2 among 4840 controls (0.04%; odds ratio\u2009=\u20098.67, 95% confidence interval\u2009=\u20091.89 to 80.52, P&amp;lt; .001), with more than half of the carriers having no personal or family history of ovarian cancer. In addition, the association was highly statistically significant among cases with estrogen-negative (P &amp;lt;. 001) or\u00a0triple-negative cancer (P &amp;lt; .001), but not in estrogen-positive cases. Tumor sequencing from carriers confirmed bi-allelic inactivation in all the triple-negative cases and was associated with high homologous recombination deficiency scores and mutational signature 3 indicating homologous recombination repair deficiency.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study provides evidence that germline loss-of-function variants of RAD51C are associated with hereditary breast cancer, particularly triple-negative type. RAD51C-null breast cancers possess similar genomic and clinical features to BRCA1-null cancers and may also be vulnerable to DNA double-strand break inducing chemotherapies and poly ADP-ribose polymerase inhibitors.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jnci\/djz045","type":"journal-article","created":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T09:11:50Z","timestamp":1554282710000},"page":"1332-1338","source":"Crossref","is-referenced-by-count":32,"title":["Combined Tumor Sequencing and Case-Control Analyses of RAD51C in Breast Cancer"],"prefix":"10.1093","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1578-9561","authenticated-orcid":false,"given":"Na","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5048-1549","authenticated-orcid":false,"given":"Simone","family":"McInerny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6528-891X","authenticated-orcid":false,"given":"Magnus","family":"Zethoven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1170-4690","authenticated-orcid":false,"given":"Dane","family":"Cheasley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belle W X","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone M","family":"Rowley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Devereux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norah","family":"Grewal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1906-7649","authenticated-orcid":false,"given":"Somayeh","family":"Ahmadloo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jue Er Amanda","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen B","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"John","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoland","family":"Antill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5681-2022","authenticated-orcid":false,"given":"Kylie L","family":"Gorringe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4361-4657","authenticated-orcid":false,"given":"Paul A","family":"James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian G","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,4,5]]},"reference":[{"issue":"5","key":"2019121310473984900_djz045-B1","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/ng.570","article-title":"Mutation of the RAD51C gene in a Fanconi anemia-like disorder","volume":"42","author":"Vaz","year":"2010","journal-title":"Nat Gen"},{"issue":"5","key":"2019121310473984900_djz045-B2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/ng.569","article-title":"Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene","volume":"42","author":"Meindl","year":"2010","journal-title":"Nat Genet"},{"issue":"1","key":"2019121310473984900_djz045-B3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10549-014-3078-4","article-title":"RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families","volume":"147","author":"Blanco","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"2019121310473984900_djz045-B4","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/ng.2224","article-title":"Germline RAD51C mutations confer susceptibility to ovarian cancer","volume":"44","author":"Loveday","year":"2012","journal-title":"Nat Genet"},{"issue":"1","key":"2019121310473984900_djz045-B5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/humu.21625","article-title":"Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients","volume":"33","author":"Thompson","year":"2012","journal-title":"Hum Mutat"},{"issue":"16","key":"2019121310473984900_djz045-B6","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1093\/hmg\/ddr229","article-title":"RAD51C is a susceptibility gene for ovarian cancer","volume":"20","author":"Pelttari","year":"2011","journal-title":"Hum Mol Genet"},{"issue":"9","key":"2019121310473984900_djz045-B7","doi-asserted-by":"crossref","first-page":"e25632.","DOI":"10.1371\/journal.pone.0025632","article-title":"RAD51C germline mutations in breast and ovarian cancer cases from high-risk families","volume":"6","author":"Clague","year":"2011","journal-title":"PLoS One"},{"issue":"2","key":"2019121310473984900_djz045-B8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10549-015-3674-y","article-title":"Identification of six pathogenic RAD51C mutations via mutational screening of 1228 Danish individuals with increased risk of hereditary breast and\/or ovarian cancer","volume":"155","author":"Jonson","year":"2016","journal-title":"Breast Cancer Res Treat"},{"issue":"26","key":"2019121310473984900_djz045-B9","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.2015.61.2408","article-title":"Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population","volume":"33","author":"Song","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019121310473984900_djz045-B10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/path.5055","article-title":"Molecular analysis of PALB2-associated breast cancers","volume":"245","author":"Lee","year":"2018","journal-title":"J Pathol"},{"key":"2019121310473984900_djz045-B11","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djy028","article-title":"The landscape of somatic genetic alterations in breast cancers from ATM germline mutation carriers","author":"Weigelt","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2019121310473984900_djz045-B12","doi-asserted-by":"crossref","first-page":"3.","DOI":"10.1186\/s13058-017-0929-z","article-title":"Evaluating the breast cancer predisposition role of rare variants in genes associated with low-penetrance breast cancer risk SNPs","volume":"20","author":"Li","year":"2018","journal-title":"Breast Cancer Res"},{"issue":"10","key":"2019121310473984900_djz045-B13","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41588-018-0206-9","article-title":"Mutations in RECQL are not associated with breast cancer risk in an Australian population","volume":"50","author":"Li","year":"2018","journal-title":"Nat Genet"},{"issue":"13","key":"2019121310473984900_djz045-B14","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1200\/JCO.2015.63.7454","article-title":"Panel testing for familial breast cancer: calibrating the tension between research and clinical care","volume":"34","author":"Thompson","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019121310473984900_djz045-B15","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s10549-016-3944-3","article-title":"Reevaluation of RINT1 as a breast cancer predisposition gene","volume":"159","author":"Li","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"2019121310473984900_djz045-B16","doi-asserted-by":"crossref","first-page":"11479.","DOI":"10.1038\/ncomms11479","article-title":"The somatic mutation profiles of 2 433 breast cancers refines their genomic and transcriptomic landscapes","volume":"7","author":"Pereira","year":"2016","journal-title":"Nat Commun"},{"volume-title":"R: A Language and Environment for Statistical Computing","year":"2016","key":"2019121310473984900_djz045-B17"},{"issue":"21","key":"2019121310473984900_djz045-B18","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1158\/0008-5472.CAN-12-1470","article-title":"Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1\/2 inactivation","volume":"72","author":"Popova","year":"2012","journal-title":"Cancer Res"},{"issue":"10","key":"2019121310473984900_djz045-B19","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/ng.3934","article-title":"A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer","volume":"49","author":"Polak","year":"2017","journal-title":"Nat Genet"},{"issue":"4","key":"2019121310473984900_djz045-B20","doi-asserted-by":"crossref","first-page":"R47.","DOI":"10.1186\/bcr2334","article-title":"Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes","volume":"11","author":"Stefansson","year":"2009","journal-title":"Breast Cancer Res"},{"issue":"1","key":"2019121310473984900_djz045-B21","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.celrep.2018.03.076","article-title":"Genomic and molecular landscape of DNA damage repair deficiency across the Cancer Genome Atlas","volume":"23","author":"Knijnenburg","year":"2018","journal-title":"Cell Rep"},{"issue":"3","key":"2019121310473984900_djz045-B22","doi-asserted-by":"crossref","first-page":"211.","DOI":"10.1186\/bcr3670","article-title":"Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers","volume":"16","author":"Watkins","year":"2014","journal-title":"Breast Cancer Res"},{"issue":"7438","key":"2019121310473984900_djz045-B23","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nature11935","article-title":"Replication stress links structural and numerical cancer chromosomal instability","volume":"494","author":"Burrell","year":"2013","journal-title":"Nature"},{"issue":"10","key":"2019121310473984900_djz045-B24","doi-asserted-by":"crossref","first-page":"R215.","DOI":"10.1186\/gb-2007-8-10-r215","article-title":"High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer","volume":"8","author":"Chin","year":"2007","journal-title":"Genome Biol"},{"issue":"1","key":"2019121310473984900_djz045-B25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.molonc.2014.07.019","article-title":"A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer","volume":"9","author":"Vollan","year":"2015","journal-title":"Mol Oncol"},{"key":"2019121310473984900_djz045-B26","doi-asserted-by":"crossref","first-page":"9.","DOI":"10.1186\/s40364-015-0033-4","article-title":"Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs","volume":"3","author":"Marquard","year":"2015","journal-title":"Biomark Res"},{"issue":"15","key":"2019121310473984900_djz045-B27","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","article-title":"Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer","volume":"22","author":"Telli","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2019121310473984900_djz045-B28","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1158\/2159-8290.CD-11-0206","article-title":"Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents","volume":"2","author":"Birkbak","year":"2012","journal-title":"Cancer Discov"},{"issue":"10","key":"2019121310473984900_djz045-B29","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/bjc.2012.451","article-title":"Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer","volume":"107","author":"Abkevich","year":"2012","journal-title":"Br J Cancer"},{"issue":"3","key":"2019121310473984900_djz045-B30","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10549-008-0117-z","article-title":"Prediction of BRCA1-association in hereditary non-BRCA1\/2 breast carcinomas with array-CGH","volume":"116","author":"Joosse","year":"2009","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"2019121310473984900_djz045-B31","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/humu.21625","article-title":"Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients","volume":"33","author":"Thompson","year":"2012","journal-title":"Hum Mutat"},{"key":"2019121310473984900_djz045-B32","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djy106","article-title":"Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing","author":"Shimelis","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"2019121310473984900_djz045-B33","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1158\/1078-0432.CCR-14-1894","article-title":"Breast cancers with a BRCA1-like DNA copy number profile recur less often than expected after high-dose alkylating chemotherapy","volume":"21","author":"Schouten","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2019121310473984900_djz045-B34","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","article-title":"Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial","volume":"19","author":"Loibl","year":"2018","journal-title":"Lancet Oncol"},{"issue":"5","key":"2019121310473984900_djz045-B35","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","article-title":"Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial","volume":"24","author":"Tutt","year":"2018","journal-title":"Nat Med"},{"issue":"6","key":"2019121310473984900_djz045-B36","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1158\/1535-7163.MCT-12-0950","article-title":"RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib","volume":"12","author":"Min","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"2019121310473984900_djz045-B37","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2147\/DDDT.S130809","article-title":"Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer","volume":"12","author":"Colombo","year":"2018","journal-title":"Drug Des Devel Ther"},{"issue":"4","key":"2019121310473984900_djz045-B38","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/1758834016687254","article-title":"PARP inhibitors in ovarian cancer: evidence, experience and clinical potential","volume":"9","author":"Evans","year":"2017","journal-title":"Ther Adv Med Oncol"},{"issue":"6","key":"2019121310473984900_djz045-B39","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ejmg.2018.01.015","article-title":"Mutational analysis of RAD51C and RAD51D genes in hereditary breast and ovarian cancer families from Murcia (southeastern Spain)","volume":"61","author":"Sanchez-Bermudez","year":"2018","journal-title":"Eur J Med Genet"},{"issue":"2","key":"2019121310473984900_djz045-B40","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s10689-015-9785-0","article-title":"Large genomic rearrangements in the familial breast and ovarian cancer gene BRCA1 are associated with an increased frequency of high risk features","volume":"14","author":"James","year":"2015","journal-title":"Fam Cancer"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/111\/12\/1332\/31513065\/djz045.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/111\/12\/1332\/31513065\/djz045.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T10:49:11Z","timestamp":1576234151000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/111\/12\/1332\/5428180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,5]]},"references-count":40,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,4,5]]},"published-print":{"date-parts":[[2019,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djz045","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"type":"print","value":"0027-8874"},{"type":"electronic","value":"1460-2105"}],"subject":[],"published-other":{"date-parts":[[2019,12]]},"published":{"date-parts":[[2019,4,5]]}}}